A Study on BRCA1/2 Mutations, Hormone Status and HER-2 Status in Korean Women with Early-onset Breast Cancer
![]() |
Choi, Doo-Ho
(Departments of Radiation Oncology, Soonchunhyang University College of Medicine)
Jin, So-Young (Departments of Pathology, Soonchunhyang University College of Medicine) Lee, Dong-Wha (Departments of Pathology, Soonchunhyang University College of Medicine) Kim, Eun-Seog (Departments of Radiation Oncology, Soonchunhyang University College of Medicine) Kim, Yong-Ho (Departments of Radiation Oncology, Soonchunhyang University College of Medicine) |
1 | Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 2000;59:185-192 DOI ScienceOn |
2 | Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006;17:391-400 DOI ScienceOn |
3 | Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-1668 DOI PUBMED ScienceOn |
4 | Park BW, Kim SI, Kim EK, Yang WI, Lee KS. Impact of patients age on the outcome of primary breast cancer. J Surg Oncol 2002;80:12-18 DOI ScienceOn |
5 | Armed JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population- based study. Cancer Res 1999;59:2011-2017 PUBMED |
6 | Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 DOI ScienceOn |
7 | Palacious J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-3614 PUBMED |
8 | Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002;62:1481-1488 PUBMED |
9 | Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003;97:1-11 DOI ScienceOn |
10 | Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000;63: 213-223 DOI ScienceOn |
11 | Choi DH, Lee MH, Haffty BG. Is the BRCA germline mutation a prognostic factor in Korean patients with early-onset breast carcinomas? J Korean Soc Ther Radiol Oncol 2003;21:149-157 |
12 | Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-371 DOI ScienceOn |
13 | Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31 PUBMED |
14 | Lakhani SR, Easton DF, Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carries of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-1510 DOI ScienceOn |
15 | Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG, and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarial cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514 PUBMED |
16 | Kang HC, Kim IJ, Park JH, et al. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat 2002;20:235 PUBMED |
17 | Ministry of Health and Welfare. Annual report of the Central Cancer Registry in Korea, Seoul. Ministry of Health and Welfare 2001 |
18 | Erola H, Heikkaila P, Tamminen A, Aittomaki K, blomqvist C, Nevanlinna H. Histopathological features of breast tumors in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R93-100 DOI ScienceOn |
19 | Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 2006;70:496-501 DOI ScienceOn |
20 | Loman N, Johannsson O, Bendahl PO, Borg A, Femo M, Olsson H. Steroid receptors in hereditary breast carcinoma s associated with BRCA1or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-319 DOI ScienceOn |
21 | Musolino A, Bella MA, Bortesi B et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 2007;16:280-292 DOI ScienceOn |
22 | Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease free survival in women with operable breast cancer. BMC Cancer 2004;17:82 |
23 | EL tamer M, Russo D, Troxel A, et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surgical Oncol 2004;11:157-164 DOI |
24 | Ahn SH, Son BH, Yoon KS, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 2007;245:90-95 DOI ScienceOn |
25 | Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318 DOI ScienceOn |
26 | Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004;22:1638-1645 DOI ScienceOn |
27 | Choi DH, Lee MH, Haffty BG. Double heterozygotes for non_Caucasian families with mutations in BRCA-1 and BRCA-2 genes. Breast J 2006;12:216-220 DOI ScienceOn |
28 | Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-752 DOI ScienceOn |
29 | Johnnesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian Cancer patients. Cancer Res 1996;56:3663-3665 |
30 | Eerola H, Vahteristo P, Sarantaus L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 2001;93:368-372 DOI ScienceOn |
31 | Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-, and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867-876 DOI ScienceOn |
![]() |